InvestorsHub Logo
Followers 0
Posts 142
Boards Moderated 0
Alias Born 06/02/2018

Re: None

Tuesday, 09/26/2023 9:30:01 AM

Tuesday, September 26, 2023 9:30:01 AM

Post# of 21531
New press release points to upcoming paper with results. Looks good.

Synaptogenix Announces Peer-Reviewed Publication of NIH-Sponsored Phase 2 Clinical Trial Results Demonstrating Safe, Significant, and Persistent Benefits of Bryostatin-1 in Advanced Alzheimer's Disease

Bryostatin-1 benefits in severe Alzheimer's disease patients were statistically significant with respect to placebo at p < 0.007


https://content.iospress.com/articles/journal-of-alzheimers-disease/jad230868
Volume:
Day Range:
Bid:
Ask:
Last Trade Time:
Total Trades:
  • 1D
  • 1M
  • 3M
  • 6M
  • 1Y
  • 5Y
Recent SNPX News